We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Insulet (PODD - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 69.1% compared to the same period last year. Revenues are forecasted to be $615.49 million, representing a year-over-year increase of 26%.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Insulet metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total Omnipod' at $605.82 million. The estimate indicates a year-over-year change of +26.1%.
Analysts expect 'Revenue- Drug Delivery' to come in at $9.07 million. The estimate indicates a change of +12% from the prior-year quarter.
Analysts predict that the 'Revenue- International Omnipod' will reach $171.85 million. The estimate suggests a change of +34.2% year over year.
Analysts' assessment points toward 'Revenue- U.S. Omnipod' reaching $433.99 million. The estimate points to a change of +23.2% from the year-ago quarter.
Insulet shares have witnessed a change of -4.3% in the past month, in contrast to the Zacks S&P 500 composite's +1% move. With a Zacks Rank #3 (Hold), PODD is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Insulet (PODD - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 69.1% compared to the same period last year. Revenues are forecasted to be $615.49 million, representing a year-over-year increase of 26%.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
In light of this perspective, let's dive into the average estimates of certain Insulet metrics that are commonly tracked and forecasted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total Omnipod' at $605.82 million. The estimate indicates a year-over-year change of +26.1%.
Analysts expect 'Revenue- Drug Delivery' to come in at $9.07 million. The estimate indicates a change of +12% from the prior-year quarter.
Analysts predict that the 'Revenue- International Omnipod' will reach $171.85 million. The estimate suggests a change of +34.2% year over year.
Analysts' assessment points toward 'Revenue- U.S. Omnipod' reaching $433.99 million. The estimate points to a change of +23.2% from the year-ago quarter.
View all Key Company Metrics for Insulet here>>>Insulet shares have witnessed a change of -4.3% in the past month, in contrast to the Zacks S&P 500 composite's +1% move. With a Zacks Rank #3 (Hold), PODD is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .